Last reviewed · How we verify
ACI-24.060 at Dose B
ACI-24.060 at Dose B is a Biologic drug developed by AC Immune SA. It is currently in Phase 1 development.
At a glance
| Generic name | ACI-24.060 at Dose B |
|---|---|
| Sponsor | AC Immune SA |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACI-24.060 at Dose B CI brief — competitive landscape report
- ACI-24.060 at Dose B updates RSS · CI watch RSS
- AC Immune SA portfolio CI
Frequently asked questions about ACI-24.060 at Dose B
What is ACI-24.060 at Dose B?
ACI-24.060 at Dose B is a Biologic drug developed by AC Immune SA.
Who makes ACI-24.060 at Dose B?
ACI-24.060 at Dose B is developed by AC Immune SA (see full AC Immune SA pipeline at /company/ac-immune-sa).
What development phase is ACI-24.060 at Dose B in?
ACI-24.060 at Dose B is in Phase 1.
Related
- Manufacturer: AC Immune SA — full pipeline